VICTORIA, BC, Nov. 19, 2020 /CNW/ - IMMUNOPRECISE
ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF)
(FSE: TQB2), a leader in full-service, therapeutic antibody
discovery and development, today announced that it has entered into
a research agreement with Genmab A/S (Nasdaq: GMAB), an
international biotechnology company specializing in the creation
and development of differentiated antibody therapeutics for the
treatment of cancer. IPA will generate novel bispecific
antibody combinations using Genmab's proprietary DuoBody® platform
and IPA's proprietary antibodies in the field of infectious
disease. The development of IPA's proprietary antibodies into
DuoBody constructs enables additional, novel formulations as the
Company investigates a series of combinations in parallel.
"Partnering with Genmab aligns with IPA's mission to develop
safe and effective therapies for patients, in this case,
specifically pertaining to the growing demand in infectious
disease," said Dr. Jennifer Bath,
Chief Executive Officer of ImmunoPrecise Antibodies. "This
agreement further complements our strategy to ensure that the full
potential of our infectious disease programs is realized, which
includes establishing productive partnerships to increase
opportunities for ideal formulations with the highest safety and
efficacy profiles."
The DuoBody technology is a proprietary platform of Genmab
applied in the discovery and development of bispecific antibodies
across several therapeutic areas including cancer, hemophilia,
autoimmune, infectious, and central nervous system diseases.
DuoBody technology has been successfully used in many Genmab
internal or partnered investigational clinical therapies.
As a part of the partnership, Genmab and IPA will negotiate in
good faith an agreement for the commercial use of resulting DuoBody
products.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a
global technology platform company with end-to-end solutions
empowering companies to discover and develop therapies against any
disease. The Company's experience and cutting-edge technologies
enable unparalleled support of its partners in their quest to bring
innovative treatments to the clinic. ImmunoPrecise's full-service
capabilities dramatically reduce the time required for, and the
inherent risk associated with, conventional multi-vendor product
development. For further information,
visit www.immunoprecise.com or contact
solutions@immunoprecise.com.
Forward Looking Information
This news release
contains statements that, to the extent they are not recitations of
historical fact, may constitute "forward-looking statements" within
the meaning of applicable Canadian securities laws. The Company
uses words such as "may", "would", "could", "will", "likely",
"expect", "believe", "intend", "should" and similar expressions to
identify forward-looking statements. Any such forward-looking
statements are based on assumptions and analyses made by
ImmunoPrecise in light of its experience and its perception of
historical trends, current conditions and expected future
developments. However, whether actual results and developments will
conform to ImmunoPrecise's expectations and predictions is subject
to any number of risks, assumptions and uncertainties. Many factors
could cause ImmunoPrecise's actual results to differ materially
from those expressed or implied by the forward-looking statements
contained in this news release. Such factors include, among other
things, actual revenues and earnings for IPA being lower than
anticipated, and those risks and uncertainties described in
ImmunoPrecise's annual management discussion and analysis for the
previous quarter ended July 31, 2020
which can be accessed at www.sedar.com. The
"forward-looking statements" contained herein speak only as of the
date of this press release and, unless required by applicable law,
ImmunoPrecise undertakes no obligation to publicly update or revise
such information, whether as a result of new information, future
events or otherwise.
Neither the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release. SOURCE ImmunoPrecise
Antibodies
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunoprecise-and-genmab-enter-into-a-technology-partnership-targeting-infectious-disease-301176558.html
SOURCE ImmunoPrecise Antibodies Ltd.